AptarGroup (NYSE:ATR) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• AptarGroup beat quarterly expectations: The company reported $1.52 in EPS, $0.05 above consensus, while revenue reached $1.02 billion versus estimates of $980.76 million.
• Shares rose 2.8% to $130.78 following the results. Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $164.14.
• Insiders have sold 23,197 shares worth approximately $3.13 million over the past three months, while company insiders retain a 0.73% ownership stake.

AptarGroup (NYSE:ATR - Get Free Report) announced its earnings results on Thursday. The industrial products company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.05, Zacks reports. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $980.76 million. AptarGroup had a net margin of 9.22% and a return on equity of 13.31%.

AptarGroup Trading Up 2.8%

AptarGroup stock traded up $3.62 during trading hours on Thursday, hitting $130.78. The stock had a trading volume of 649,713 shares, compared to its average volume of 491,301. The business's 50 day simple moving average is $125.84 and its 200-day simple moving average is $126.92. The stock has a market cap of $8.32 billion, a price-to-earnings ratio of 23.65, a P/E/G ratio of 3.92 and a beta of 0.34. AptarGroup has a one year low of $103.23 and a one year high of $146.91. The company has a quick ratio of 1.10, a current ratio of 1.61 and a debt-to-equity ratio of 0.42.

Insider Buying and Selling

In related news, insider Shiela Vinczeller sold 765 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $130.37, for a total value of $99,733.05. Following the transaction, the insider directly owned 26,313 shares in the company, valued at $3,430,425.81. This trade represents a 2.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Hedi Tlili sold 8,854 shares of AptarGroup stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $135.00, for a total value of $1,195,290.00. Following the transaction, the insider owned 15,379 shares of the company's stock, valued at $2,076,165. This trade represents a 36.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 23,197 shares of company stock valued at $3,134,828. Company insiders own 0.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ATR shares. UBS Group initiated coverage on AptarGroup in a research report on Friday, October 9th. They issued a "neutral" rating and a $135.00 target price on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of AptarGroup in a research note on Monday, September 21st. Wells Fargo & Company raised their target price on AptarGroup from $145.00 to $155.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Raymond James Financial reissued an "outperform" rating and issued a $160.00 target price on shares of AptarGroup in a research note on Wednesday, July 15th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of AptarGroup in a research note on Wednesday, October 7th. They issued a "buy" rating and a $150.00 price target on the stock. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $164.14.

AptarGroup Company Profile

AptarGroup, Inc NYSE: ATR develops and manufactures dispensing, sealing and delivery systems for the pharmaceutical, beauty, personal care, food and beverage markets. Its products are designed to control, protect and dispense a wide range of liquids, creams, lotions, fragrances and other formulations.

The company's offerings include pumps, valves, closures, aerosol systems and other dispensing components, as well as drug-delivery technologies. Through its pharmaceutical business, Aptar supports nasal, pulmonary, ophthalmic, dermal and injectable applications, serving pharmaceutical and biotechnology companies with components and systems used in prescription, over-the-counter and consumer health products.

Aptar serves customers internationally through manufacturing, research and development and commercial operations across North America, Europe, Asia and other global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.